Clinical Pharmacology & Biopharmaceutics
Open Access

Clinical Pharmacology and Biopharmaceutics (CPB) from OMICS Publishing Group is one of the renowned journals in Pharmaceutical Sciences and has been publishing research articles, review articles, case reports, short communications, and conference proceedings since 2011. As an open-access publication platform, CPB features the independent research work from various fields of pharmaceutical sciences like Pharmacology, Clinical Pharmacology, Pharmacometrics, Pharmacokinetics & Pharmacodynamics, Research Methods and Statistics, Applied Biopharmaceutics, Clinical Drug Trials, Methods in Clinical Pharmacology, Biopharmaceutics and Drug Distribution, Biopharmaceutics and Process Validation, Pharmacoeconomics, Clinical Trial Databases, Medical Trials, Process Validation, and many more emerging topics.

CPB is a quarterly journal and its presence is covered in different indexing sights like index Copernicus, publons, CAS Source Index (CASSI), Sherpa Romeo, Genamics JournalSeek, EBSCO A-Z, OCLCWorldCat. In CPB, all published articles are assigned to Digital Object Identifier (DOI) – CrossRef. To enable the outreach of the publications and outstanding published researches and for industry news, our Assistant Managing Editor Alina Grace put best efforts to share the recent developments through twitter and LinkedIn professional accounts.

So far CPB has published nine volumes to date. Despite COVID-19 challenges in 2020, CPB has stayed focused on its objectives of publishing world-class research articles and engaging reviews. In 2020, CPB received many valuable types of research from across the globe and has published 12 publications in forms of short communications, minireviews, and research surpassing the number of articles published in 2019. The acceptance of publications in CPB is purely based on fair and blind peer-review using an editorial managing system. Our eminent peer reviewers are renowned scientific and regulatory professionals from different universities across the globe, pharmaceutical industry, and federal agencies.

As there is a paradigm shift to hasten the drug development due to urgent needs, the emerging fields like Clinical Pharmacology and Pharmacometrics play crucial roles to translate chemical entities from bench-to-bedside. With a future vision to incorporate recent technological advancements in drug development, CPB in additional to traditional scientific approaches also encourage researchers to share their contributions in model-informed drug-development approaches like the application of ‘big-data’ in health care, application of pharmacogenomics-based trials, different approaches to address variability in exposures and responses and researches based on different model-based platforms to address optimum trial design and dose selection. Through such contributions, CPB envisages to stay ahead with recent developments and contribute to educating the global research community.

As the newly appointed Editor in the Editorial Board of CPB, I would like to take this opportunity to thank and acknowledge the efforts of the Editorial Board, Editor-in-Chief: Shufeng Zhou, Executive Editors, and Fellow Editors for rendering tireless efforts to streamline quality innovative research articles and reviews free from plagiarism. I would like to express my deep gratitude to the authors, reviewers, publishers, and office bearers for supporting us over the years and building CPB into a premier publication platform in pharmaceutical sciences.